thought new manag structur post-clos
new manag structur draw strength compani
morn bristol announc new manag structur combin new compani celgen acquisit ith
giovanni caforio remain ceo previous announc current bristol leadership remain head commerci
organ celgen provid hematolog head think move posit draw ing respect
strength compani line ith previou commentari compani see takeaw ay ceo/cfo call ith bristol
replay inform includ continu support deal expect time close follow ed
success integr compani maintain overw eight rate bristol ith pt equal eight celgen ith
celgen manag take lead new organ new function ill tw core area research earli
develop global drug develop rupert vessey ch phil celgen current presid research
earli develop ill lead ed think new compani ill benefit leadership help develop celgen current
pipelin hich major driver deal global drug develop ill led new hire samit hiraw ay ho
evp/head oncolog develop novarti
bristol manag head commerci hematolog leadership come celgen commerci effort ill continu
led bristol current evp chief commerci offic chri boerner ph ithin commerci organ nadim
ahm celgen current presid global hematolog oncolog ill overse hematolog busi includ cell therapi
view maintain bristol current strong commerci capabl hile supplement ith celgen hematolog expertis
good strategi celgen current cfo david elkin ill becom cfo combin compani current bristol cfo charl
bancroft ill retir year ith compani
pleas see bmy-celg pro forma model global io model attach
recent quot strategi
look combin compani opportun launch new medicin next month potenti opportun
extraordinari time increas number phase asset compani continu
invest broad life cycl manag program opdivo immuno-oncolog franchis compani signific
expertis small molecul combin compani great experi expertis biolog lead franchis cell
therapi great peopl compani look forward bring togeth real passion scienc innov
patient giovanni caforio chairman board ceo
realli excit opportun bring togeth compani rapidli grow busi market
opportun potenti launch new product littl year quit uniqu five product come
celgen everi one littl bit differ four launch opportun hematolog segment celgen know
extrem well compani giovanni caforio chairman board ceo
combin mid-size compani lean employe base limit manufactur network larg overlap
geographi plan immedi focus protect integr core busi function larg acquisit
past complementari natur busi believ ring-fenc key team function minim
distract exampl critic mass oncolog solid tumor celgen hematolog expect maintain
focu minim disrupt research commerci function compani charl bancroft execut vice-president global
give us call ith question comment geoff greg olivia jason scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu use blend averag price/grow th basi base averag larg cap
global therapeut group hich view appropri given primari focu specialti drug/biotechnology-ori
compani discount cash flow analysi assign equal eight tw methodolog deriv price target
per share
risk may imped achiev barclay research valuat price grow th prospect
increasingli depend deliveri immuno-oncolog pipelin setback delay could pose risk stock field
immuno-oncolog get increasingli competit bristol leadership challeng major player particularli
merck keytruda competit disadvantag term clinic develop regulatori timelin could put pressur
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog price target base price-to-earnings multipl support sum-of-th part npv analysi
use base busi assign revlimid pom/ thal/ vidaza otezla
abraxan pipelin assign luspatercept ozanimod combin ith
equity/ platform valu ye net cash support pt
risk may imped achiev barclay research valuat price commerci risk increas
preval mm revlimid strong competit posit provid signific tailw ind could drive upsid forecast
mani product biotech industri high price point celgen product includ revlimid differ
surpris certain region select payor segment pushback cost
decis made use less expens treatment altern increas adopt strategi could neg impact
celgen oper perform share price clinic risk celgen deep pipelin drug candid intern
partner compani develop across rang diseas mani drug early-to-mid stage
develop could fail meet target endpoint trial fail demonstr meaning clinic benefit
outcom could put impair celgen abil launch new drug could pressur share perform litig patent
risk patent relat celgen key product revlimid focu on-going litig hich could lead market entri
gener revlimid prior compani expect gener revlimid enter market prior street expect revlimid
sale could fall celgen share ould neg impact gener celgen reli patent protect
invest drug develop gener entrant celgen brand product could harm futur sale regulatori risk
celgen broad pipelin could result posit late stage data ever posit data guarante fda
ema ill grant approv delay timelin inabl gain approv could significantli impact celgen futur sale
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
